Stages of company formation
The GPHC company was established in 2020. We specialize in the production of medicines, as well as in their medical promotion in the pharmaceutical market. We hope that our customers will help us develop and become better.
November 2020
We have obtained a license for pharmaceutical activity
We have approved the strategy for the development of the product portfolio until 2024. We have started developing the first medicines.
April 2022
Received registration certificates for medicines
We have received registration certificates for the medicines IMIPENEM+CILASTATIN-GPHC® and MEROPENEM-GPHC®.
May 2022
Received a registration certificate for CEFOPERAZONE+SULBACTAM-GPHC®
The drug is used to treat infectious and inflammatory diseases of the upper and lower respiratory tract, urinary tract and other diseases caused by microorganisms sensitive to the drug.
December 2022
Received a registration certificate for BIAPENEM-GPHC®
The drug is used to treat diseases caused by microorganisms sensitive to biapenem: pneumonia, complicated cystitis, pyelonephritis, peritonitis and others.
January 2023
Received registration certificates for medicines
We have received registration certificates for medicines CEFUROXIME-GPHC®,
PIPERACILLIN+TAZOBACTAM-GPHC® and XONOCTAM®.
PIPERACILLIN+TAZOBACTAM-GPHC® and XONOCTAM®.
February 2023
Received a registration certificate for the drug SULBACTAM-GPHC®
The drug is used to treat diseases caused by strains of microorganisms sensitive to the combination of sulbactam with beta-lactam antibiotics.
